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Pneumonia is the greatest contributor to childhood mortality and morbidity in resource-
poor regions, while in high-income countries it is one of the most common reasons for
clinic attendance and hospitalization in this age group. Furthermore, pneumonia in chil-
dren increases the risk of developing chronic pulmonary disorders in later adult life. While
substantial advances in managing childhood pneumonia have been made, many issues
remain, some of which are highlighted in this perspective. Multiple studies are required as
many factors that influence outcomes, such as etiology, patient characteristics, and pre-
vention strategies can vary between and within countries and regions. Also, outside of
vaccine studies, most randomized controlled trials (RCTs) on pneumonia have been based
in resource-poor countries where the primary aim is usually prevention of mortality. Few
RCTs have focused on medium to long-term outcomes or prevention.We propose different
tiers of primary outcomes, where in resource-rich countries medium to long-term sequelae
should also be included and not just the length of hospitalization and readmission rates.
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WHY CHILDHOOD PNEUMONIA IS IMPORTANT
Childhood pneumonia is of worldwide importance for several
reasons. Firstly, while many illnesses receive relatively more atten-
tion, pneumonia remains the most important cause of mortality
and morbidity in young children globally (1, 2). Secondly, deaths
from pneumonia are largely preventable in this age group. Thirdly,
pneumonia, especially when recurrent, is linked to future chronic
lung disease (3). Thus, interventions that reduce pneumonia and
acute lower respiratory infections (ALRIs) have both short and
long-term benefits. This perspective is not a comprehensive review
of childhood pneumonia and its management. Instead, it aims to
highlight the many gaps in our knowledge so as to stimulate and
improve clinical research in pneumonia that will lead subsequently
to improved clinical care.
GLOBAL PNEUMONIA BURDEN
Pneumonia is the largest (18%) single cause of death in children
aged <5-years (1). Global estimates of the annual incidence of
pneumonia in children aged <5-years range from 120 to 160
million episodes, with more than 99% occurring in resource-
limited countries (1). While there are substantial inter-country
and inter-continental differences in the annual incidence of pneu-
monia [0.33 episodes per child-year in Africa, 0.05 in developed
countries (1, 2)], there is also intra-continental (4) and wide
intra-country variability (1, 5). For example, in South Amer-
ica, the percentage of childhood deaths under the age of 5-
years attributable to pneumonia is much lower in Chile and
Uruguay (5–10%) than in Bolivia, Peru, and Guyana (15–20%)
(4). Also, in contrast to the rest of affluent Australia, ALRIs
(encompassing pneumonia) are the commonest cause of pre-
ventable deaths in infants, emergency medical retrievals from
remote communities, and hospitalizations among Indigenous
children aged<5-years (6, 7). Hospitalized-pneumonia incidence
of infants in the Northern Territory of Australia (the region
with the highest proportion of Indigenous people) is 0.43 per
child-year (8). Similarly, Indigenous children in New Zealand
and the United States (US) also bear a substantially dispropor-
tionate burden of disease (9, 10). Nevertheless, while there is
little doubt that socio-economic issues are important, pneumo-
nia remains one of the most common causes of hospitalization
in children, even in resource-rich countries where before the
widespread adoption of pneumococcal conjugate vaccines (PCVs)
an estimated 1.5 million children aged <5-years were admitted
annually.
THE KNOWLEDGE GAPS
Epidemiological estimates of pneumonia depend upon the accu-
racy of data collection,which is problematic because of: (a) absence
of a diagnostic gold standard, (b) lack of resources to collect data
systematically (especially in resource-poor countries), and (c) con-
siderable intra-country variation making extrapolation of data
subject to biases, especially when universal health systems are sub-
optimal and people seek treatment in the private sector (where
data capture is more difficult).
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ETIOLOGY
Acute lower respiratory infections are caused by several respi-
ratory viral and bacterial pathogens, often in combination with
one another. Major viral causes of ALRI and pneumonia in
infants and children include respiratory syncytial virus, influenza,
adenoviruses, parainfluenza 3, and human metapneumovirus.
While viruses are the predominant cause of ALRIs, especially
in the young, respiratory bacterial pathogens are most often
implicated in childhood deaths from pneumonia (1). The pre-
dominant bacterial pathogen is Streptococcus pneumoniae, which
dominates across all age groups, but other important pathogens
include Haemophilus influenzae, Staphylococcus aureus and, in
older children, Mycoplasma pneumoniae (11). Other common
causes of severe pneumonia are measles in regions where vac-
cine uptake is poor, non-typhoid Salmonella species in regions of
Africa where malaria is endemic, Klebsiella pneumoniae in mal-
nourished children and neonates, and Pneumocystis jirovecii and
Mycobacterium tuberculosis, especially in HIV positive infants and
children.
Current studies determining the etiology of pneumonia vary
substantially with respect to factors that influence the diagnosis
and ascribed microbial etiology. These include case definitions,
use of and interpretation of chest x-rays (CXR), peripheral blood
white cell counts, and inflammatory markers, depth of investi-
gations, facility type, and patient characteristics. Consequently,
studies describe different frequency and types of pathogens asso-
ciated with pneumonia. The Pneumonia Etiology Research for
Child Health (PERCH) project is the largest multisite study (6000
children, 7 African and Asian countries) of childhood pneumo-
nia. It seeks to address the aforementioned limitations by using
case-control methodologies and adopting a protocol that has
standardized enrollment criteria, specimen collection, laboratory
testing, and molecular detection techniques (12).
THE KNOWLEDGE GAPS
Despite advances in identifying microorganisms using highly sen-
sitive molecular techniques, ascribing causation is problematic.
Nucleic acid amplification (NAA) techniques, such as polymerase
chain reaction (PCR) assays, identify genetic material, but the
implicated microbe may no longer be viable or infectious and
their presence may be from a recent, but unrelated respira-
tory illness. For example, the prevalence of respiratory viruses
detected by molecular techniques in asymptomatic children is
as high as 42% (13) and strains of adenovirus C may remain
latent in mucosal lymphocytes and be shed for months or even
years (14).
Even when the same molecular detection techniques for viruses
are used, the site of specimen collection influences results. In
paired comparisons of concurrently obtained upper and lower air-
way specimens for respiratory viruses in 75 children, we found sig-
nificant discordance between nasopharyngeal aspirate and bron-
choalveolar lavage (BAL) specimens (manuscript submitted) (15).
The discordance was dependent on the virus type and most
marked for human rhinovirus and adenoviruses. Additionally, we
(16) and others (17) have found that even when investigating viral
infections from a single specimen collection site, detection of mul-
tiple viral types is not uncommon. This observation compounds
the difficulty in determining the primary causative agent and
presents new questions about the roles of these viruses in the
etiology of the disease.
The ideal samples for determining etiologic agents in bacterial
pneumonia are lower airway specimens. It is usually neither nec-
essary nor feasible to obtain either BAL or needle lung aspirate
specimens in acute pneumonia. Induced sputum is an alterna-
tive only in older children, and as potential respiratory bacterial
pathogens commonly colonize the upper airways of healthy chil-
dren, oropharyngeal contamination can complicate interpretation
of culture results. Blood cultures are also infrequently (<10%)
positive in children with pneumonia and as PCVs become incor-
porated into national immunization schedules their sensitivity
is likely to be further reduced (18). PCR techniques have only
modestly increased the yield of pathogen detection in blood sam-
ples (19), while with the exception of M. pneumoniae, serology is
impractical in most clinical situations. Thus, it remains a challenge
to determine the ideal, yet feasible, specimen for identifying the
etiological agent(s) in pneumonia.
Increasingly, viral–viral, viral-bacterial, and bacterial–bacterial
interactions in the pathogenesis of respiratory infections are recog-
nized with in vitro and in vivo animal (20) and human studies (21,
22). Thus, although viruses may initiate the respiratory infection,
secondary bacterial infection may occur, and simply identifying
a virus at presentation (leading to antibiotics being with-held)
may not indicate the sole etiology of the child’s acute clinical
presentation or determine its long-term outcomes.
The complexity of the microbial contribution is further
increased by introducing the world of “-omics” (e.g., metage-
nomics). While interest in this field is exploding, its use may fur-
ther complicate ascribing etiology to a single organism. Although
analysis of gene expression signatures shows considerable promise
for identifying causative pathogens of pneumonia (23), these and
other NAA platforms (e.g., microbead arrays, microarray) are
unlikely to be made available in the near future to resource-
poor countries where the burden of childhood pneumonia is
greatest.
PREVENTION AND CONTRIBUTING FACTORS
Vaccines, such as pertussis, measles, and more recently Hib and
PCVs, have reduced the worldwide incidence of pneumonia (24).
However, the benefit from population vaccination programs is
not always uniform, as for example in the case of PCV-7, which
although having significantly reduced pneumonia rates in tar-
get and some older age groups (24), its impact on other pop-
ulations living in resource-rich nations has been surprisingly
limited. Despite achieving high population PCV-7 vaccination
rates of ∼90%, the incidence of World Health Organization
(WHO)-defined radiographic pneumonia was not reduced in
the Indigenous population living in the Northern Territory of
Australia (25).
In resource-poor nations, important factors identified for
increasing the risk of pneumonia include overcrowding, access to
clean water, malnutrition, anemia, young maternal age, low birth
weight, and exposure to tobacco smoke and other environmental
pollutants. Several of these risk factors also contribute to children
in resource-rich nations developing pneumonia.
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THE KNOWLEDGE GAPS
The contribution of asthma or asthma-like illness to pneumo-
nia remains controversial (26). While people with asthma have
minor intrinsic abnormalities in their immune responses (27)
leading to a predisposition to viral lung infections and occasion-
ally invasive pneumococcal disease, it is also possible that some
children with asthma may have been misdiagnosed as pneumo-
nia (26). Further information on the contribution (e.g., mis-
diagnosis or co-morbidity) of the asthma phenotype to early
childhood pneumonia, especially in resource-limited countries,
is warranted (26).
Good hygiene practices reduce ALRIs and promotion of
safe hygiene is the single most cost-effective means of pre-
venting infectious disease (28). However, how best to make
safe hygiene practices a matter of daily routine is yet to be
determined (28).
In some settings, such as in Indigenous settings in the US and
Australia, a combination of factors underlie why the young chil-
dren living in remote communities experience a high burden of
pneumonia. While housing is very important, housing upgrades
can be insufficient to improve health outcomes in children and a
broader approach is required (29). Exactly what this entails is yet
to be determined, but factors likely to be important are adequate
water supply and minimizing indoor air pollution.
DIAGNOSIS
Current case definitions for pneumonia vary considerably and
are highly setting dependent (18). In WHO-defined pneumonia,
cough or breathing difficulties, and age-adjusted tachypnea are
sufficient for diagnosing mild-to-moderate pneumonia, but these
criteria were designed for health workers with relatively little train-
ing. However, the diagnostic thresholds for respiratory rate differ
between the WHO, US, and United Kingdom (UK) guidelines (30,
31). Furthermore, even within affluent countries such as the US,
the diagnostic criteria, and testing for pneumonia within hospital
Emergency Departments varies widely (32).
Community healthcare workers often diagnose pneumonia on
history and examination (respiratory rate, dyspnea, auscultatory
findings). However, in young children with a cough, chest aus-
cultatory findings, even by doctors (general practitioners), are
unreliable with kappa values (0.39, 95% CI 0.26–0.53) (33) below
the acceptable clinical range.
While many studies use CXRs as the gold standard (18), there
is disagreement over whether a CXR should be an index test. Cur-
rent USA (31) and UK (34) guidelines on childhood pneumonia do
not advocate CXRs outside of hospital settings. Furthermore, their
interpretation is subjective often resulting in additional diagnos-
tic variability. Also, CXRs are insensitive when compared to chest
computed tomography (CT) scans (35). While chest CT scans will
not be used to diagnose pneumonia in the usual clinical setting,
the poor sensitivity of CXRs means they too cannot be used as a
diagnostic gold standard.
Laboratory tests (e.g., C-reactive protein, peripheral blood
white cell count, erythrocyte sedimentation rate) are ancillary and
non-diagnostic tests. In adults with community-acquired pneu-
monia, employing procalcitonin levels to initiate and cease antibi-
otics might be useful, however, procalcitonin diagnostic thresholds
in childhood pneumonia are less defined and their usefulness and
safety in guiding management has not been established (18).
THE KNOWLEDGE GAPS
World Health Organization has published a standardized method
to define radiographic pneumonia (based on CXRs) for epidemi-
ological studies and vaccine trials (36). The WHO definition for
primary endpoint consolidation WHO-EPC (36) was framed to
be more specific for likely bacterial pneumonia than those used for
clinical purposes. However, some authors have applied the WHO-
EPC definition in the clinical context (24), an approach that we
do not recommend (37). In a blinded study, a pediatric pulmo-
nologist’s assessment of radiographic pneumonia in a cohort of
children hospitalized with clinical pneumonia, had significantly
higher positive predicted value for the presence of auscultatory
crackles and elevated peripheral blood white cell counts when
compared to WHO-EPC read by a panel standardized to inter-
pret WHO-EPC (37). Others have raised similar concerns, with
left lower and right middle lobe consolidation and non-alveolar
pneumonia causing the greatest levels of disagreement (37, 38).
A systematic review compared 11 different “gold standards” for
identifying bacterial pneumonia and found that diagnostic tests
used for pediatric pneumonia have not been validated rigorously
(18). Some advocate chest ultrasounds for diagnosing pneumonia
(24), but this approach has not been validated. While chest ultra-
sounds may provide adequate images of some lobes, they will not
for others, particularly the right middle lobe. Thus, using another
sub-optimal diagnostic tool will only complicate the field further.
The lack of a universally agreed diagnostic gold standard for
childhood pneumonia, especially one that can also differentiate
between bacterial and non-bacterial pneumonia is a major limi-
tation in clinical research in this area. Vaccine probes have proven
useful at a population level, but they under-estimate the bur-
den of disease as no vaccine is 100% efficacious or, in the case
of PCVs, protects against all disease causing serotypes. Instead,
valid standards useful for various scenarios should be devel-
oped. These include standards for clinical, epidemiological, and
treatment purposes, such as defining when antibiotics should be
used (as opposed to conceptually a purely bacterial or viral-based
etiology).
MANAGEMENT
Managing childhood pneumonia relies upon several factors:
a. Child factors
• Demographics (e.g., age, immunization status, household
contacts, etc.)
• Severity of pneumonia (e.g., hypoxemia, complications)
• Co-morbidities (e.g., malnutrition, HIV, other immunodefi-
ciencies, malaria, underlying cardiac, pulmonary, neuromus-
cular, or metabolic disorders)
b. External factors
• Country (health care facilities)
• Setting (urban vs. rural; hospital vs. community)
Pneumonia case management, especially in resource-poor
regions, is important (39). These focus on: (a) antimicrobial ther-
apy when appropriate, (b) correcting hypoxemia, (c) fluid and
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nutritional management, (d) treatment of co-morbidities, and (e)
close observation for developing complications. National treat-
ment guidelines exist (31, 34), but there is wide variability in
managing pneumonia, even in resource-rich countries (40).
THE KNOWLEDGE GAPS
Some issues specific to pneumonia management in resource-poor
settings were highlighted recently (39). These included difficulties
in differentiating clinically between pneumonia and other com-
mon serious illnesses in infants and young children living in these
regions, such as bronchiolitis and malaria, issues over when to refer
for inpatient management, antibiotic choice when HIV, tubercu-
losis, and Salmonella infections are common, micronutrients use,
definition of hypoxemia, and defining and managing treatment
failure in the acute setting.
While basic management principles are known, the details of
the “how, when and what” remain uncertain. For example, with
oxygen; when should it be initiated, what pulse oxygen saturation
should be targeted once oxygen supplementation is commenced
and how best to deliver oxygen (pure or mixed, high or low flow)
is still unknown. Because of the cost implications for resource-
poor countries and randomized controlled trial (RCT) evidence
that high concentration oxygen therapy may result in adverse out-
comes in adults with acute asthma (41), these issues that might
seem unimportant, are highly relevant in improving clinical care.
The many RCTs involving antibiotics have so far only focused
on short-term outcomes and increasingly shorter courses of
antibiotics have been advocated. None however, have focused on
the length of wet or productive cough post-treatment. As with
oxygen, while this may appear unimportant, the persistence of
chronic wet cough (signifying persistence of excessive airway secre-
tions and lower airway infection) is associated with developing
bronchiectasis in children (42).
Further, outside of vaccine trials, most RCTs on treating pneu-
monia in the last two decades were based in resource-poor
areas (30) where risk factors, etiology, patient characteristics, and
settings differ substantially from resource-rich countries. Meta-
analysis of studies have shown discrepancies in results between
studies conducted in resource-poor vs. resource-rich settings (43).
Those conducted in resource-poor regions have in some cases had
significantly more favorable treatment effects than in resource-rich
settings (43).
The primary objective of childhood pneumonia management
has focused largely on preventing mortality in resource-poor
countries and reducing hospitalization rates in resource-rich
nations. Here, we propose three tiers for managing pneumonia
in children. With the increasing awareness of chronic disease in
developing countries (including lung disease) and that a substan-
tial amount of chronic lung disease originates in childhood (42,
44, 45), in an ideal world all tiers should be targeted at clinical
practice. The main objectives of each tier and on-going research
questions within each of these objectives include:
a. Preventing mortality
Identifying who needs hospitalization
Recognizing who needs oxygen
When to start antibiotics and in whom and for how long?
b. Reducing short-term morbidity
Type and duration of antibiotic courses
Duration of oxygen supplementation and weaning
Identifying and treating co-morbidities, including malnutri-
tion
Preventing and managing complications
c. Promoting return to full and long-term health
Identifying and treating on-going symptoms post-acute
episode
Preventing recurrences and long-term sequelae
CONSEQUENCES OF PNEUMONIA
ACUTE PHASE
Simple pneumonia may evolve into complicated pneumonia,
defined by developing parapneumonic effusions, empyema, pyop-
neumothorax, or necrotizing pneumonia. Interestingly, the inci-
dence of complicated pneumonia has increased over the last two
decades and has occurred in countries before and after introduc-
ing PCVs into the immunization schedule (46), although there are
encouraging signs from the UK that the incidence may now be
declining after changing from a PCV-7 to PCV-13 schedule. How-
ever, it is beyond the scope of this article to discuss complicated
pneumonia further.
SHORT-TERM
Few studies have closely followed-up children with pneumonia.
In a study of 78 Australian Indigenous children hospitalized with
pneumonia and followed for 12-months afterward, 26% had new
treatable chronic respiratory symptoms identified (47). Mean-
while, in a New Zealand study, 74% of the 81 children with
an adequately performed CXR 10–14 months post-hospitalization
for an ALRI had features of on-going respiratory morbidity (wet
cough, auscultatory chest crackles, CXR abnormalities) (5).
LONG-TERM
The alveolar stage of human lung development occurs from 36-
weeks gestation and continues for at least 7-years post-natally (48).
Hence, early infectious or inflammatory insults in the first few
years of life, when postnatal lung development is the most impor-
tant, are most likely to result in long-term effects. While low birth
weight can influence future lung function, there is increasing evi-
dence that early life events, such as pneumonia, are at least equally
important determinants of adult lung dysfunction, as shown in
human and animal studies (44, 45, 49, 50).
In adult cohort studies, recurrent ALRIs are independent risk
factors for subsequent chronic obstructive pulmonary disease (44,
49), although they did not confirm the history of prior childhood
pneumonia. There are very few long-term pediatric follow-up
studies. One case-control study on bronchiectasis showed that
hospitalized pneumonia was a risk factor, particularly when it
was recurrent and/or severe (51). An English study of 103 chil-
dren found that children post (median 5.6-years) hospitalized
pneumonia were significantly more likely to have persistent cough
or asthma than controls (52). Similarly, a Gambian-based study
showed that 68 children hospitalized previously with pneumonia
had significantly higher odds (2.8, 95% CI 1.1–7.4) of chronic lung
disease at follow-up 12–14 years later (53).
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THE KNOWLEDGE GAP
Many gaps in persistent morbidity and long-term sequelae from
pneumonia exist. The concept of the post-bronchiolitis syndrome
is appreciated increasingly (54) and in the last decade the WHO
has emphasized the origins of adult chronic lung disease from early
in life and that potential intervention trials should begin during
this critical developmental stage of lung growth and development.
SUMMARY
We have highlighted some of the key knowledge gaps in diag-
nosing and managing childhood pneumonia. Clinical trials are
now needed in various settings to address these gaps. We propose
a tiered approach and a framework to advance this field so as to
reduce the short and long-term burden associated with pneumonia
in children.
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